{"nctId":"NCT00345683","briefTitle":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","startDateStruct":{"date":"2007-07"},"conditions":["Haemophilus Influenzae Type b","Neisseria Meningitidis"],"count":4021,"armGroups":[{"label":"Menhibrix Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)","Biological: Prevnar","Biological: M-M-R II","Biological: Varivax"]},{"label":"ActHIB Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: PedvaxHIB","Biological: Prevnar","Biological: M-M-R II","Biological: Varivax"]}],"interventions":[{"name":"GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)","otherNames":[]},{"name":"PedvaxHIB","otherNames":["Monovalent Hib conjugate vaccine."]},{"name":"Prevnar","otherNames":[]},{"name":"M-M-R II","otherNames":["Measles","mumps and rubella vaccine."]},{"name":"Varivax","otherNames":["Varicella vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects enrolled in the primary study (NCT00345579) are eligible for participating in the booster study\n\nExclusion Criteria:\n\nSubjects should not be administered M-M-R II and Varivax if any of these criteria apply:\n\n* History of measles, mumps, rubella or varicella.\n* Previous vaccination against measles, mumps, rubella or varicella.\n* Hypersensitivity to any component of the vaccines, including gelatin or neomycin.\n* Patients receiving immunosuppressive therapy.\n* Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems.\n* Individuals with primary and acquired immunodeficiency states.\n* Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.\n* Individuals with active tuberculosis.\n* Acute disease at time of booster vaccination","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"15 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting New Onset of Chronic Illnesses (NOCIs)","description":"NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Rash","description":"Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With New Onset of Chronic Illnesses (NOCIs)","description":"NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Rash","description":"Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Adverse Events Resulting in Emergency Room (ER) Visits","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":72,"n":3010},"commonTop":[]}}}